Towards the prevention of schizophrenia

Biological Psychiatry

Volumn 48, Issue 5, 2000, Pages 349-356

  Tsuang, Ming T ^a,b,c   Stone, William S ^a,c   Faraone, Stephen V ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Genetics; Negative symptoms; Neuropsychology; Risperidone; Schizotaxia

Indexed keywords

RISPERIDONE;

DRUG EFFECT; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

HUMANS; SCHIZOPHRENIA;

EID: 0034282757     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)00934-3     Document Type: Review

References (55)

1. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS). 1983;The University of Iowa, Iowa City.
2. Auerbach J., Hans S., Marcus J. Neurobehavioral functioning and social behavior of children at risk for schizophrenia. Isr J Psychiatry Relat Sci. 30:1993;40-49.
3. Battaglia M., Torgersen S. Schizotypal disorder at the crossroads of genetics and nosology . Acta Psychiatr Scand. 94:1996;303-310.
4. Beauregard M., Bachevalier J. Neonatal insult to the hippocampal region and schizophrenia a review and a putative animal model . Can J Psychiatry. 41:1996;446-456.
5. Cassens G., Inglis A.K., Appelbaum P.S., Gutheil T.G. Neuroleptics Effects on neuropsychological function in chronic schizophrenic patients . Schizophr Bull. 16:1990;477-499.
6. Catts S.V., McConaghy N., Ward P.B., Fox A.M., Hadzi-Pavlovic D. Allusive thinking in parents of schizophrenics. Meta-analysis. J Nerv Ment Dis. 181:1993;298-302.
7. Dworkin R., Lewis J., Cornblatt B., Erlenmeyer-Kimling L. Social competence deficits in adolescents at risk for schizophrenia. J Nerv Ment Dis. 182:1994;103-108.
8. Erlenmeyer-Kimling L (2000): Neurobehavioral deficits in offspring of schizophrenic parents: Liability indicators and predictors of illness. Am J Med Genet 97:65-71.
9. Erlenmeyer-Kimling L., Cornblatt B., Friedman D., Marcuse Y., Rutschmann J., Simmens S., Devi F. Neurological, electrophysiological, and attentional deviations in children at risk for schizophrenia. Henn F.A., Nasrallah H.A., Schizophrenia as a Brain Disease. 1982;61-98 Oxford University Press, New York.
10. Falloon I.R.H., Kydd R.R., Coverdale J.H., Laidlaw T.M. Early detection and intervention for initial episodes of schizophrenia. Schizophr Bull. 22:1996;271-282.
11. Faraone SV, Green AI, Seidman LJ, Tsuang MT (in press): "Schizotaxia": Clinical implications and new directions for research. Schizophr Bull.
12. Faraone S.V., Kremen W.S., Lyons M.J., Pepple J.R., Seidman L.J., Tsuang M.T. Diagnostic accuracy and linkage analysis How useful are schizophrenia spectrum phenotypes? Am J Psychiatry. 152:1995;1286-1290.
13. Faraone S.V., Seidman L.J., Kremen W.S., Pepple J.R., Lyons M.J., Tsuang M.T. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients A diagnostic efficiency analysis . J Abnorm Psychol. 104:1995;286-304.
14. Faraone S.V., Tsuang D., Tsuang M.T. Genetics of Mental Disorders A Guide for Students, Clinicians, and Researchers . 1999;Guilford, New York.
15. Friedman D., Squires-Wheeler E. Event-related potentials (ERPs) as indicators of risk for schizophrenia. Schizophr Bull. 20:1994;63-74.
16. Goldman-Rakic P.S. More clues to "latent" schizophrenia point to developmental origins. Am J Psychiatry. 152:1995;1701-1703.
17. Gottesman I.I. Schizophrenia Genesis The Origin of Madness . 1991;Freeman, New York.
18. Green A.I., Schildkraut J.J. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard Rev Psychiatry. 3:1995;1-9.
19. Green M.F., Marshall B.D.J., Wirshing W.C., Ames D., Marder S.R., McGurk S., et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry. 154:1997;799-804.
20. Hymowitz P., Frances A., Jacobsberg L.B., Sickles M., Hoyt R. Neuroleptic treatment of schizotypal personality disorders. Compr Psychiatry. 27:1986;267-271.
21. Ingraham L.K., Kugelmass S., Frenkel E., Nathan M., Mirsky A.F. Twenty-five year follow-up of the Israeli High-Risk study Current and lifetime psychopathology . Schizophr Bull. 21:1995;183-192.
22. Knoll J.L., Garver D.L., Ramberg J.E., Kingsbury S.J., Croissant D., McDermott B. Heterogeneity of the psychoses Is there a neurodegenerative psychosis? Schizophr Bull. 24:1998;365-379.
23. Kremen W.S., Seidman L.J., Pepple J.R., Lyons M.J., Tsuang M.T., Faraone S.V. Neuropsychological risk indicators for schizophrenia A review of family studies . Schizophr Bull. 20:1994;103-119.
24. Larsen T.K., Opjordsmoen S. Early identification and treatment of schizophrenia Conceptual and ethical considerations . Psychiatry. 59:1996;371-380.
25. Levy D.L., Holzman P.S., Matthysse S., Mendell N.R. Eye tracking and schizophrenia A selective review . Schizophr Bull. 20:1994;47-62.
26. Lieberman J.A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia A rationale and hypothesis . J Clin Psychiatry. 57:(suppl 11):1996;68-71.
27. Loebel A.D., Lieberman J.A., Alvir J.M.J., Mayerhoff D.I., Geisler S.H., Szymanski D.O. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 149:1992;1183-1188.
28. Marder S., Meibach R. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835.
29. McGlashan T.H. Early detection and intervention in schizophrenia Research . Schizophr Bull. 22:1996;327-345.
30. McGlashan T.H., Johannessen J.O. Early detection and intervention with schizophrenia Rationale . Schizophr Bull. 22:1996;201-222.
31. McGorry P.D., Edwards J., Mihalopoulos C., Harrigan S.M., Jackson H.J. EPPIC An evolving system of early detection and optimal management . Schizophr Bull. 22:1996;305-326.
32. McGorry P.D., McFarlane C., Patton G.C. The prevalence of prodromal features of schizophrenia in adolescence A preliminary survey . Acta Psychiatr Scand. 92:1995;241-249.
33. Meehl P.E. Schizotaxia, schizotypy, schizophrenia. Am Psychol. 17:1962;827-838.
34. Meehl P.E. Schizotaxia revisited. Arch Gen Psychiatry. 46:1989;935-944.
35. Olin S.C., Mednick S.A. Risk factors of psychosis Identifying vulnerable populations premorbidly . Schizophr Bull. 22:1996;223-240.
36. Park S., Holzman P.S., Goldman-Rakic P.S. Spatial working memory deficits in the relatives of schizophrenic patients. Arch Gen Psychiatry. 52:1995;821-828.
37. Robins E., Guze S.B. Establishment of diagnostic validity in psychiatric illness Its application to schizophrenia . Am J Psychiatry. 126:1970;983-987.
38. Rossi A., Mancini F., Stratta P., Mattei P., Gismondi R., Pozzi F., Casacchia M. Risperidone, negative symptoms and cognitive deficit in schizophrenia An open study . Acta Psychiatr Scand. 95:1997;40-43.
39. Seidman L.J. The neuropsychology of schizophrenia A neurodevelopmental and case study approach . J Neuropsychiatry. 2:1990;301-312.
40. Seidman L.J. Clinical neuroscience and epidemiology in schizophrenia. Harvard Rev Psychiatry. 3:1997;338-342.
41. Seidman L.J., Faraone S.V., Goldstein J.M., Goodman J.M., Kremen W.S., Matsuda G., et al. Reduced subcortical brain volumes in nonpsychotic siblings of schizophrenic patients A pilot MRI Study . Am J Med Genet. 74:1997;507-514.
42. Stip E. The effect of Risperidone on cognition in patients with schizophrenia. Can J Psychiatry. 41:1996;S35-S40.
43. Tamminga C.A. The promise of new drugs for schizophrenia treatment. Can J Psychiatry. 42:1997;265-273.
44. Tsuang M.T. Genes, environment, and mental health wellness. Am J Psychiatry. 157:2000;489-491.
45. Tsuang M.T., Faraone S.V. The case for heterogeneity in the etiology of schizophrenia. Schizophr Res. 17:1995;161-175.
46. Tsuang M.T., Gilbertson M.W., Faraone S.V. Genetic transmission of negative and positive symptoms in the biological relatives of schizophrenics. Marneros A., Tsuang M.T., Andreasen N., Positive vs. Negative Schizophrenia. 1991;265-291 Springer-Verlag, New York.
47. Tsuang M.T., Stone W.S., Seidman L.J., et al. Treatment of nonpsychotic relatives of patients with schizophrenia Four case studies . Biol Psychiatry. 45:1999;1412-1418.
48. Vaglum P. Earlier detection and intervention in schizophrenia Unsolved questions . Schizophr Bull. 22:1996;347-352.
49. Weinberger D.R. Neurodevelopmental perspectives on schizophrenia. Bloom F.E., Kupfer D.J., Psychopharmacology The Fourth Generation of Progress . 1995;1171-1183 Raven, New York.
50. Weinberger DR (1995b): Schizophrenia as a neurodevelopmental disorder: A review of the concept. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. London: Blackwell Science, 293-323.
51. Woods B.T. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry. 155:1998;1661-1670.
52. Wyatt R.J. Early intervention for schizophrenia Can the course of the illness be altered? Biol Psychiatry. 38:1995;1-3.
53. Wyatt R.J., Apud J.A., Potkin S. New directions in the prevention and treatment of schizophrenia A biological perspective . Psychiatry. 59:1996;357-370.
54. Yung A.R., McGorry P.D., McFaarlane C.A., Jackson H.J., Patton G.C., Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 22:1996;283-304.
55. Zornberg G.L., Buka S.L., Tsuang M.T. Hypoxic ischemia-related fetal/neonatal complications and risk of schizophrenia and other nonaffective psychoses A 19-year longitudinal study . Am J Psychiatry. 157:2000;196-202.